Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
about
Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic LandscapesPediatric solid tumor genomics and developmental pliancyOverview and recent advances in the treatment of neuroblastoma.Microfluidics for genome-wide studies involving next generation sequencing.Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation.A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?Pediatric Rhabdomyosarcoma.What is new in the biology and treatment of pediatric rhabdomyosarcoma?Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis.Identification of ALK gene alterations in urothelial carcinoma.Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations.Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences.Notch signaling in pediatric soft tissue sarcomasRelationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcomaTargeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.Clonality and evolutionary history of rhabdomyosarcomaNovel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumorsNeuroblastoma: developmental biology, cancer genomics and immunotherapy.A versatile modular vector system for rapid combinatorial mammalian geneticsTargeted therapies for advanced Ewing sarcoma family of tumors.MURC/cavin-4 Is Co-Expressed with Caveolin-3 in Rhabdomyosarcoma Tumors and Its Silencing Prevents Myogenic Differentiation in the Human Embryonal RD Cell Line.Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study.Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma.Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.Kras activation in p53-deficient myoblasts results in high-grade sarcoma formation with impaired myogenic differentiationUndifferentiated pleomorphic sarcoma with co-existence of KRAS/PIK3CA mutationsProbing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases.The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growthSecreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar RhabdomyosarcomaDistinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments.
P2860
Q53996682-8947E6CF-083F-4F84-8EED-DBCF1AFDB344Q54606055-6E677461-3494-4C0C-A5C5-B6FC482854FBQ54606924-4BE5B6C5-DCFB-4196-BD96-E346567EC21EQ54808333-336F797B-313F-49F4-8F81-D37C6D98CB94Q54817048-E7901E35-E24E-4168-9C6A-441B5B6F0C7AQ54899015-9835648A-D11E-473A-8B65-38932B91664FQ54899054-CFD8C69B-C6AA-4B7A-AEF1-AC6F2097ED3BQ54905539-65CFC938-2E14-4939-B16B-5C3A36C83BB6Q54949532-2842C847-B149-49B6-B2D3-66587F3FFDFFQ54949536-6CDE3257-6620-49A4-A4D8-525B7EA03999Q54950334-389255EA-D479-4E33-81C2-8A176E1D9BEDQ54950336-4A61B197-3867-455F-83B1-E9E98380BE2FQ54950341-1EB8FAE1-DE6F-4999-B020-8CD2D23437F7Q54950346-2AEF237A-0160-4DEC-BC2A-4365ED72CCDAQ54950715-32AF7F0D-9DE1-4802-9ADB-9BC5E5C55D0CQ54952464-EE6642C7-0C38-4F7F-8066-026D7FD99657Q54953654-956A8995-2B6F-4D25-8544-29D39914A98FQ54954519-3D128BDB-B090-457B-BE93-6D695CFD17E7Q54954985-0EBD64EE-78D2-437A-8FA5-EF223074D24FQ54971813-C48460A2-D68E-4871-8C62-741CCF2DA5D6Q54971816-54DF0A36-074C-4F7F-A028-1F1750259CFBQ54973055-EE289D7F-A0E9-42E6-86E7-E1DE55B42CA7
P1343
Q26801785-D474133F-2BF7-4185-B8F3-396D3C54CD1AQ27023560-54E71102-950D-4272-A4D1-3FE7A8B824BDQ30238693-66F326C2-951F-4A3E-B614-4EEB7C713488Q30359014-B4FE32D1-6742-4AF5-A4F8-66A13D916A7AQ30418118-BF801897-35CA-455E-8F76-338B1EBDFEA9Q30455659-8F186C7B-C7C7-4288-AC87-B51F1E0D7FA2Q33438006-49C8DD4F-56AB-4706-B042-993934B02605Q33751398-247C83F9-EB93-4E20-9B50-224168603953Q33842070-BC5D0D20-7E49-4566-A48E-8215EBEB9432Q33895506-38FB9CDA-4D18-470B-8066-C7AED70B49C9Q33940017-C81F436E-66EC-47E8-B5C6-340D7BB65E55Q33989002-2AABAA8D-1D48-4A67-A53C-BE321ACA0BCCQ34028920-2266D684-4011-4C24-ACFF-BA06EAF73EB9Q34474029-3BC4A938-780E-4F33-AC38-E3401D2E793EQ34480012-019781AD-CEF7-4BE0-87E7-7328299A791CQ34486201-76AA5CC4-26D7-4564-8A66-CEEC797EEED4Q34507108-474D866C-B467-4684-B691-CFDB17783A39Q34525925-F6A49B62-B4AE-4695-AA71-1CE4F26F2FC8Q34635079-5AAC96ED-0C64-4D43-9990-AC3187CE40AEQ35017004-09926A19-FE84-4C54-8231-8B7204F53ACAQ35096201-31FD2CF0-2435-4C99-A2A2-44EC0FBA317EQ35175269-D8ED5C75-C4C5-49A0-9279-924347CCAFEEQ35224188-C32AD2E1-64F0-4984-BE06-A6393ADBF571Q35283020-5486AFED-CCFC-4E12-B827-67218637B60AQ35408740-6FDD1E25-6FAB-439C-8F9F-00DF2EBF9E71Q35589492-560AC7AE-22B5-4D89-AEB1-FCF4BEDC09C3Q35667137-5014B167-E832-4B92-B2C9-0CBE29D48D70Q35711420-B25F0FD4-92F1-42B0-85D2-49D89D01CA9AQ35752926-448A0403-4622-4572-8635-44B4A7369C0AQ35819280-0AE2E80E-B056-47EA-BDA6-C2DCAFEB8646Q35939402-072A7C3A-D120-4E3F-9B4C-B291C31C2651Q35987311-6E7031F1-361F-47A8-9092-35C1288B662AQ36014509-70CFAD33-FCF8-48F9-90D7-373B03447873Q36142754-8B5E98AC-4DB6-4F8F-876B-BDD1963C2E19Q36346641-13006EDB-CB1F-42F3-8487-B12EB7374050Q36386881-6164EDE8-0DC5-4F8E-BB33-285B8DA8CC43Q36460093-7F943540-18F9-4C9F-A8C9-F6D859D43B5FQ36545304-E0326430-FB94-4E24-A129-5DB0D4664EC2Q36623378-18508F0B-2CAA-4614-B820-55813D29A9BAQ36903863-B6F36875-E608-4432-8349-675CB6FBE420
P2860
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Oncogene mutation profiling of ...... in growth signaling pathways.
@ast
Oncogene mutation profiling of ...... in growth signaling pathways.
@en
type
label
Oncogene mutation profiling of ...... in growth signaling pathways.
@ast
Oncogene mutation profiling of ...... in growth signaling pathways.
@en
prefLabel
Oncogene mutation profiling of ...... in growth signaling pathways.
@ast
Oncogene mutation profiling of ...... in growth signaling pathways.
@en
P2093
P2860
P4510
P1476
Oncogene mutation profiling of ...... in growth signaling pathways.
@en
P2093
Angela Marchetti
Chyau-Yueh Lau
Frederic G Barr
Ismail Yilmaz
Khedoudja Nafa
Laetitia Borsu
Nabahet Ameur
Neerav Shukla
P2860
P304
P356
10.1158/1078-0432.CCR-11-2056
P407
P50
P577
2011-12-05T00:00:00Z